Part III. High-Throughput Sequencing and Applications

Why Sequence DNA?


- All genes available for an organism to use -- a very important tool for biologists
- Not just sequence of genes, but also positioning of genes and sequences of regulatory regions



Evolution of Sequencing Technology

First Generation Sequencing

• Sanger Sequencing [1977]




Next (or second) Generation Sequencing (NGS)

• Massively parallel sequencing [2006/2007]

Third Generation Sequencing

• Singel molecule sequencing [2013]

Fourth Generation Sequencing?








The Advancement of HTS by Human Genome Project


- It all starts with human genome project (1990).
 - What is in "the book of life"?
 - How many genes are there in human genome?
 - The International Human Genome Sequencing Consortium published their analysis of the 'draft' sequence in February 2001; and the finished, 'gold standard' sequence in 2004.





HTS advantages:

- Rapid
- Low cost
- Enables the sequencing of complete DNA sequences, or genomes of numerous types and species of life.



Mass sequencing AT^{GC}TTAGTA TAGC^{CT}GAT CCA^{GTAGTO}

by Viktor S. Poór

HTS Sequencers

Next generation sequencers

- 454 / Roche sequencing
- Illumina (Solexa) sequencing
- SOLiD systems
- Ion Torrent sequencing

Third generation sequencers

- PacBio RS II (Pacific Biosciences)
- MinION (Oxford Nanopore)






NEW HiSeq 2500

	Focused power.		Flexible	e power.	Production power.	Population power.		
	-							
	MiSe	eq Series O	NextSeq	Series O	HiSeq Series O	HiSeq X Series ⊘		
Key Methods	Small genome, amplicon, and targeted gene panel sequencing.		, and transcriptom	nome, exome, e sequencing, more.	Production-scale genome, exome, transcriptome sequencing, and more.	Population- and production-scale human whole-genome sequencing.	numan whole-genome	
	HiSec	2500	HiSeq 3000	HiSeq 4000	HiSeq X Five*	HiSeq X Ten*		
Run Mode	Rapid Run	High- Output	N/A	N/A	N/A	N/A		
Flow Cells per Run	1 or 2	1 or 2	1	1 or 2	1 or 2	1 or 2		
Output Range	10-300 Gb	50-1000 Gb	125-750 Gb	125-1500 Gb	900-1800 Gb	900-1800 Gb		
Run Time	7-60 hours	<1-6 days	<1-3.5 days	<1-3.5 days	<3 days	<3 days		
Reads per Flow Cell [†]	300 million	2 billion	2.5 billion	2.5 billion	3 billion	3 billion		
Maximum Read Length	2 x 250 bp	2 x 125 bp	2 x 150 bp	2 x 150 bp	2 x 150 bp	2 x 150 bp		
System Overview	efficiency for large-		Maximum throughput and lowest cost for production-scale genomics.	Maximum throughput and lowest cost for production-scale genomics.	Maximum throughput production-scale human genome sequencing	whole- cost population-scale hu	uman	

Comparison of Sequencing Technologies


Sequencer	Sanger 3730xl	454 GS	Ion Torrent	SOLiDv 4	Illumina HiSeq 2000	Pac Bio
Mechanism	Dideoxy chain termination	Pyroseque ncing	Detection of hydrogen ion	Ligation and two- base coding	Reversible nucleotides	Single molecule real time
Read length	400-900 bp	700 bp	~400 bp	50 + 50 bp	100 bp PE	1000~10000 bp
Error Rate	0.001%	0.1%	2%	0.1%	2%	10-15%
Output data (per run)	100 KB	1 GB	100 GB	100 GB	1 TB	10 GB

Increase in Sequencing Capacity



Graph from Macmillan Publishers Ltd: Nature 458, 719-724 (2009)


Decrease in Sequencing Costs



Data from the NHGRI Genome Sequencing Program (GSP)

Cost (US dollars per MB)

General Methodology for HTS





VectorStock'

Wextor/Stock.com/22456425

1. Sampling

- Clinical material
 - Collect samples according to applicable recommendations
 - Safe transport & storage of samples (prevent degeneration)
 - Correct & complete documentation
- Cultivated material
 - Normal laboratory procedures





2. Sample Preparation


- Homogenization
- Filtration
- Enrichment
 - -Ultracentrifugation
- Extraction (RNA or DNA)




3. Pre-Amplification

- Targeted amplification (Amplicon)
- Random amplification

MDA (multiple displacement amplification) by *Phi29* DNA polymerase



Sequence-independent, single-primer amplification (SISPA)




4 & 5. Library Preparation & Sequencing

Smaller bench-top sequencer	Capacity/Time	Full size sequencer	Capacity/Time
MiSeq Illumina	~6 Gb (2 x 300) 36 hours	HiSeq Illumina	~600 Gb (2 x 100) 11 days
Ion Torrent Life Technologies	~1 Gb (400bp) 4 hours	Ion Proton Life Technologies	~30 Gb (150bp) 8-10 hours
454 Junior Roche	35 Mb (up to 400bp) 12 hours	454 GS FLX+	700 Mb (up to 1kb) 23 hours
MinION Oxford Nanopore	(up to 10kb)	PacBio RS II Pacific Biosciences	~300Mb (up to12kb) 2 hours

Mb = mega base pairs: 1,000,000 bp; Gb = giga base pairs: 1,000,000,000 bp

6. Bioinformatics & Computational Genomics




Illumina Sequencing by Synthesis (video)

HTS Applications


Whole genome sequencing •Whole exome sequencing RNA sequencing ChIP-seq/ChIP-exo CLIP-seq GRO-seq/PRO-seq Bisulfite-Seq


Selected HTS Applications



Molecular Cell, 58, 586–597 (May, 2015)


HTS application: whole genome sequencing






C5264789-A

HTS Application: RNAseq The evolution of transcriptomics



1995 P. Brown, et. al. Gene expression profiling using spotted cDNA microarray: expression levels of known genes **2002** Affymetrix, whole genome expression profiling using tiling array: identifying and profiling novel genes and splicing variants

2008 many groups, mRNA-seq: direct sequencing of mRNAs using next generation sequencing techniques (NGS)



Nature Reviews | Genetics

Figure from Wang et. al, RNA-Seq: a revolutionary tool for transcriptomics, Nat. Rev. Genetics 10, 57-63, 2009).

RNA-seq Application

- Differential expression
- Gene fusion
- Alternative splicing
- Novel transcribed regions
- Allele-specific expression
- RNA editing
- Transcriptome for non-model organisms

Benefits & Challenges of RNA-seq

Benefits:

- Independence on prior knowledge
- High resolution, sensitivity and large dynamic range
- Unravel previously inaccessible complexities

Challenges:

- Interpretation is not straightforward
- Procedures continue to evolve

ChIP-seq is Key to Epigenome Mapping

• Binding site identification and discovery of binding sequence motifs (Nonhistone ChIP)


Histone ChIP

• Epigenomic gene regulation and chromatin structure (Histone ChIP)


Non-histone ChIP

- Transcription Factors
- Where are they?
- Sequence preference
- Correlation with gene expression
- Chromatin Marks
- Where are they?
- What combinations do they come in
- How do they relate to biological status

Basic ChIP-Seq Workflow



DNA Methylation Profiling (Methylome) by HTS



BS-Seq: bisulfite sequencing;

MeDIP-Seq: methylated DNA immunoprecipitation sequencing;

RRBS-Seq: reduced representation bisulfite sequencing;

WGBS: whole genome bisulfite sequencing;

MethylCap-Seq: methylation capture sequencing;


MBD-Seq: methyl-CpG binding domain sequencing;

oxBS-Seq: oxidative bisulfite sequencing;

TAB-Seq: TET-associated bisulfite sequencing;

BSAS: bisulfite amplicon sequencing

Bisulfite-seq for Methylome Study



Sequencing: unemethylated cytosines read as thymidine in sense strand; adenine in the anti-sense strand. Other technologies evolved from here.


HTS Advances Human (Epi)Genome Project

- Human Genome Project (1990-2003)
 - Sequenced all ~20,000 genes in our DNA
 - 3 billion basepairs, ~3 billion dollars
 - -Only 1.5% of genome codes for proteins!




 Epigenomics Road Map (2008-Present)

 Goal: Create map of epigenome in multiple tissue types and cancers







Application of HTS in Clinic

- •Genomic testing
- Precision medicine

GENETICS VS. GENOMICS

GENETICS

- Genetics is the study of heredity.
- "Gene" refers to a specific sequence of DNA on a single chromosome.
- Genetics involves the study of functions and composition of the single gene.

GENOMICS


- Genomics is the study of the entirety of an organism's genes.
- "Genome" refers to an organism's entire genetic makeup.
- Genomics addresses all genes and their inter relationships.

Unlike genetics, genomics is not constrained to inheritable mutations. It identifies how your genetic makeup influences the course of a disease and, conversely, how environment, lifestyle, and drug treatments can trigger mutations that alter that course.

By understanding these ever-changing variables, doctors can make more informed choices in treatment, often preemptively.

Applications of Genomic Testing in Medicine

CAGTCACAGACCCAACT CCGAGCACTCAGGAGA CCAGGCTAGTTTTGGA CCAGGCTAGTTTTGGA GGGGGTTGGGGGGGA AGGTTTGACCCAGC GTAGAAGGTTCAG




Inherited Disease

Cancer


Reproductive Health

Genomic Alterations in Cancer

Major classes



Discovering unique therapies that treat an individual's cancer based on the specific genetic abnormalities of that person's tumor.








HTS Application in Clinics: NIPT (Non-invasive Prenatal Testing



Prof. Dennis Lo, CUHK



無創產檢獲獎港教授與霍金齊名

●本報訊 十五年前率先發現孕婦血 漿存有胎兒 DNA,推出無創產前診斷 技術的中文大學醫學院教授盧煜明, 科研貢獻揚威海外,獲美國權威組織頒 發「傑出研究獎」,是首名華人獲此殊 榮。盧教授昨稱能將科學發現變成臨床 測試,令人鼓舞,望港府及慈善團體增 加撥款及捐助,繼續推動本港科研。

免流產風險測遺傳病

盧煜明為中大醫學院講座教授兼化 學病理學系系主任,研究成果蜚聲國際。美國臨床化學協會和美國國家臨床 生物化學學院本月中在洛杉磯向盧頒發 傑出研究獎,過去曾有兩名諾貝爾得獎 者獲獎。盧去年七月已獲英國皇家學會 院士名銜,與光纖之父高觀,著名物理 學家霍金等齊名。

盧煜明與科研團隊在九七年率先發 現孕婦血漿存有胎兒 DNA,一改醫學界 認為母體與胎兒血液不相連的説法。一 〇年再突破,成功破解胎兒基因圖譜, 有助及早發現是否先天性遺傳病。他推 出名為「敏兒安 T21」無創產前診斷技 術,診斷唐氏綜合症準確度達百分之九 十九點一,免卻高危孕婦接受抽羊胎水 或絨毛的入侵性檢查,毋須面對百分之 〇點五至百分之一的流產風險。

中大醫學院為技術申請多項專利, 授權本港私家醫院或診所搜集孕婦血液 樣本測試。但盧早前公開批評有內地機 構涉嫌侵權,使用同一技術檢測。盧教 授昨表示,中大醫學院仍要諮詢法律意 見墨否追究涉嫌侵權事件。




Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma


Rossa W. K. Chiu^{a,b}, K. C. Allen Chan^{a,b}, Yuan Gao^{c,d}, Virginia Y. M. Lau^{a,b}, Wenli Zheng^{a,b}, Tak Y. Leung^e, Chris H. F. Foo^f, Bin Xie^c, Nancy B. Y. Tsui^{a,b}, Fiona M. F. Lun^{a,b}, Benny C. Y. Zee^f, Tze K. Lau^e, Charles R. Cantor^{g,1}, and Y. M. Dennis Lo^{a,b,1}




Cell Free Fetal DNA (cff DNA) in Maternal Blood




- < 1 % of total DNA in maternal circulation is fetal</p>
- 5-30 % of cell-free DNA in maternal circulation is fetal



Chiu, PNAS, 2008





5 Down syndrome
10 normal
100% accuracy
Earliest: 11 weeks

Chiu et al., Clinical Chemistry, 2010


HTS Application in Oncology

Cancer diagnosis

- Biopsy or sample removed during surgery can help identify the precise genetic origin.
- Liquid biopsies—samples of blood or urine—from which cell-free DNA (cfDNA) is isolated, avoiding the need for invasive procedures.

Cancer screening

- For people at higher risk of cancer, genetic testing for cancer predisposition can play an important role in reducing cancer mortality through prevention.
- For people with a family history of these cancers, NGS-based testing is well-suited to identifying any inherited harmful variants



HTS and Precision Medicine




Figure 2. Personalized models to guide precision medicine in advanced cancer. Illustration of our precision medicine program depicting the workflow,


HTS Application in Mendelian Diseases-Genomic Testing

- Originate from single-gene variants, for example single nucleotide polymorphisms (SNPs) and indels, that parents can pass on to their offspring, and can be dominant or recessive in nature.
- HTS can be used to efficiently analyze multiple genes simultaneously, making it well-suited to searching for rare variants in a pool of many genes.
- HTS reduces the time to find the cause of a condition, contributing substantially to the well-being of patients and their relatives



HTS Application in Microbiology and Infectious Diseases

- Primary diagnostics Detection
 - Detection, identification & characterization of previously unidentified microorganisms
 - Molecular marker profiles directly from clinical samples











Figure 1 Diagrammatic representation of main steps of clinical virus discovery by next-generation sequencer based technologies.

Coronavirus Discovery and Detection












Old techniques for genetic testing

- Karyotyping
- FISH
- PCR
- Array Comparative Genomic Hybridisation (aCGH)


Polymerase chain reaction (PCR)

- Amplify specific DNA and RNA fragments
- Once nucleotide sequence of a region of DNA strand is known, complimentary oligonucleotides & polymerase are added to single strand DNA
- Repeat process 30 times to get adequate DNA
- PCR identify specific DNA sequence for gene mutation.




Huntington gene

1 ttg ctg tgt gag gca gaa cct gcg ggg gca ggg gcg ggc tgg ttc cct ggc cag cca ttg 61 gca gag tcc gca ggc tag ggc tgt caa tca tgc tgg ccg gcg tgg ccc cgc ctc cgc cgg 121 cgc ggc ccc gcc tcc gcc ggc gca cgt ctg gga cgc aag gcg ccg tgg ggg ctg ccg gga 181 cgg gtc caa gat gga cgg ccg ctc agg ttc tgc ttt tac ctg cgg ccc aga gcc cca ttc 241 att gcc ccg gtg ctg agc ggc gcc gcg agt cqq ccc qaq qcc tcc qqq qac tqc cqt qcc 301 ggg cgg gag acc gcc atg gcg acc ctg gaa aag ctg atg aag gcc ttc gag tcc ctc aag 361 tcc ttc cag ccq ccq ccq ccq cct cct caq ctt cct caq



Encodes a run of 11-34 glutamine amino acid residues in the HD protein. A run of > 34 glutamine residues causes the protein to aggregate in the brain cells and cause progressive cell death. The data below shows the results of electrophoresis of PCR fragments amplified using probes for the site which has been shown to be altered in Huntington's disease. The male parent, as shown by the black box, got Huntington's disease when he was 40 years old. His children include 6 (3,5,7,8,10,11) with Huntington's disease, and the age at which the symptoms first began is shown by the number above the band from the PCR fragment.




Quiz:

- A. No relationship between age of onset of disease and the migration rate of PCR fragments.
- B. A shorter PCR fragment predicts early onset of Huntington's disease.
- C. Increased length of the amplified PCR fragment predicts early onset of Huntington's disease.
- D. Huntington's disease must be contagious since many of the children have the disease.

BRCA1 and BRCA2 (breast cancer, early onset) are normally expressed in the cells of breast and other tissue, where they help repair damaged DNA or destroy cells if DNA cannot be repaired. They are involved in the repair of chromosomal damage with an important role in the error-free repair of DNA double-strand breaks.

Population or subgroup	BRCA1 mutation(s)	Reference(s)			
African-Americans	943ins10, M1775R	[58]			
Afrikaners	E881X	[59]			
Ashkenazi Jewish	185delAG, 188del11, 5382insC	[54][55]			
Austrians	2795delA, C61G, 5382insC, Q1806stop	<u>[60]</u>			
Belgians	2804delAA, IVS5+3A>G	<u>[61][62]</u>			
Dutch	Exon 2 deletion, exon 13 deletion, 2804delAA	[61][63][64]			
Finns	3745delT, IVS11- 2A>G	<u>[65][66]</u>			
French	3600del11, G1710X	<u>[67]</u>			
French Canadians	C4446T	<u>[68]</u>			
Germans	5382insC, 4184del4	<u>[69][70]</u>			
Greeks	5382insC	[71]			
Hungarians	300T>G, 5382insC, 185delAG	[72]			
Italians	5083del19	[73]			
Japanese	L63X, Q934X	[74]			
Native North Americans	1510insG, 1506A>G	[75]			
Northern Irish	2800delAA	[76]			
Norwegians	816delGT, 1135insA, 1675delA, 3347delAG	[77][78]			
Pakistanis	2080insA, 3889delAG, 4184del4, 4284delAG, IVS14-1A>G	[79]			
Polish	300T>G, 5382insC, C61G, 4153delA	<u>[80][81]</u>			
Russians	5382insC, 4153delA	[82]			
Scottish	2800delAA	[<u>76][83]</u>			
Spanish	R71G	<u>[84][85]</u>			
Swedish	Q563X, 3171ins5, 1201del11, 2594delC	[<u>58][86]</u>			



Test for 5382insC mutation presence (lanes 1 and 5) or absence (lanes 2 - 4). PCR amplified fragments of exon 20 of the BRCA1 gene were subjected to electrophoresis and DNA bands were visualized by silver staining.


nCov-2019 PCR detection












		20	40
SBRp3	:	CTTTCTGATGATGCCGTCGTGTGCTACAACAGTAA	стасс :40
SBRs	:	CTTTCTGATGATGCCGTTGTGTGCTATAACAGTAA	CTATG :40
SHT or2	:	CTTTCTGATGATGCCGTTGTGTGCTA <mark>T</mark> AACAGTAAC	CTATG :40
SC	:	CTTTCTGATGATGCCGTTGTGTGCTATAACAGTAAC	CTATG :40
SB	:	CTTTCTGATGATGCCGTTGTGTGCTATAACAGTAAC	CTATG :40
SBRf1	:	CTTTCTGATGATGCCGTTGTGTGCTACAATAGTAAC	CTATG :40
SBRm1	:	CTTTCTGATGATGCCGTTGTGTGCTACAATAGTAAC	CTATG :40
SBHKU3-	1:	CTTTCTGACGATGCCGTTGTGTGCTATAATAGTAA	TACG :40
SB273	:	CTTTCTGATGATGCCGTTGTGTGCTACAATAGTAA	CTATG :40
SB279	:	CTTTCTGATGATGCCGTTGTGTGCTACAATAGTAAC	CTATG :40
11FW-mo	d:	TGATGATGCCGTCGTGTGCTACAA	:24
Consensus	seq.	CTTTCTGATGATGCCGTTGTGTGTGCTACAACAGTAA	CTATG

https://www.youtube.com/watch?v=tgyzdgf66eM

Relative positions of amplicon targets on the SARS coronavirus and the 2019 novel coronavirus genome



E: envelope protein gene; M: membrane protein gene; N: nucleocapsid protein gene; ORF: open reading frame; RdRp: RNA-dependent RNA polymerase gene; S: spike protein gene.

Primers and probes, real-time RT-PCR for 2019 novel coronavirus

Assay/use	Oligonucleotide	Sequence ^a	Concentration ^b		
	RdRp_SARSr-F	GTGARATGGTCATGTGTGGCGG	Use 600 nM per reaction		
	RdRp_SARSr-P2	FAM-CAGGTGGAACCTCATCAGGAGATGC-BBQ	Specific for 2019-nCoV, will not detect SARS-CoV.		
PdPD gono			Use 100 nM per reaction and mix with P1		
RdRP gene	RdRP_SARSr-P1	FAM-CCAGGTGGWACRTCATCMGGTGATGC-BBQ	Pan Sarbeco-Probe will detect 2019-nCo SARS-CoV and bat-SARS-related CoVs.		
			Use 100 nM per reaction and mix with P2		
	RdRp_SARSr-R	CARATGTTAAASACACTATTAGCATA	Use 800 nM per reaction		
	E_Sarbeco_F	ACAGGTACGTTAATAGTTAATAGCGT	Use 400 nm per reaction		
E gene	E_Sarbeco_P1	FAM-ACACTAGCCATCCTTACTGCGCTTCG-BBQ	Use 200 nm per reaction		
	E_Sarbeco_R	ATATTGCAGCAGTACGCACACA	Use 400 nm per reaction		
N gene	N_Sarbeco_F	CACATTGGCACCCGCAATC	Use 600 nm per reaction		
	N_Sarbeco_P	FAM-ACTTCCTCAAGGAACAACATTGCCA-BBQ	Use 200 nm per reaction		
	N_Sarbeco_R	GAGGAACGAGAAGAGGCTTG	Use 800 nm per reaction		

^a W is A/T; R is G/A; M is A/C; S is G/C. FAM: 6-carboxyfluorescein; BBQ: blackberry quencher.

^b Optimised concentrations are given in nanomol per litre (nM) based on the final reaction mix, e.g. 1.5 μL of a 10 μM primer stock solution per 25 μL total reaction volume yields a final concentration of 600 nM as indicated in the table.

Partial alignments of oligonucleotide binding regions, SARS-related coronaviruses (n = 9)

A. RdRp gene

WH-Human_1|China|2019-Dec

BetaCoV/Wuhan/IPBCAMS-WH-01/2019|EPI_ISL_402123 BetaCoV/Wuhan/IVDC-HB-01/2019|EPI_ISL 402119 BetaCoV/Wuhan/IVDC-HB-04/2020 EPI ISL 402120 BetaCoV/Wuhan/IVDC-HB-05/2019[EPI_ISL_402121 BetaCoV/Wuhan/WIV04/2019|EPI_ISL_402124 MG772933 Bat SARSrelated CoV (bat-SL-CoVZC45) NC 004718 Human SARS-related CoV (e.g. Frankfurt-1) NC_014470 Bat SARS-related CoV (BM48-31/BGR/2008)

								r.	un	Ψ	_		n,	01								ŀ	1:	
	ł	•	÷	*	R	•	•	÷	÷	•	÷	•	•	÷	•	÷	÷	÷	•	÷	÷		P2	:
	G	Т	G	A	A	A	Т	G	G	Т	С	A	Т	G	Т	G	Т	G	G	С	G	G	0	-
3						•				•	٠													•
																								•
											·													
											·													
											·													
											·													
																								÷
	٠	٠				٠	٠				т	٠		-	٠	٠				٠				

N Sarbeco F

RdRn SARSr-F

$\cdots \cdots W \cdots R \cdots \cdots M \cdots T \cdots$ CAGGTGGAACCTCATCAGGAGATGC TATGCTAATAGTGTTTTTAACATTTG

RdRp SARSr-

· · · · · · · · · · A · · · · C · · T · · · · · · · · · · · · · · · · Ā · · · · · Č · · T · · · · ·

RdRp_SARSr-R

N Sarbeco R

B. E gene

WH-Human 1|China|2019-Dec

BetaCoV/Wuhan/IPBCAMS-WH-01/2019|EPI ISL 402123 BetaCoV/Wuhan/IVDC-HB-01/2019|EPI ISL 402119 BetaCoV/Wuhan/IVDC-HB-04/2020[EPI_ISL_402120 BetaCoV/Wuhan/IVDC-HB-05/2019|EPI_ISL_402121 BetaCoV/Wuhan/WIV04/2019|EPI ISL 402124 MG772933 Bat SARS related CoV (bat-SL-CoVZC45) NC 004718 Human SARS-related CoV (e.g. Frankfurt-1) NC_014470 Bat SARS-related CoV (BM48-31/BGR/2008)

C. N gene

WH-Human 1|Chinal2019-Dec

BetaCoV/Wuhan/IPBCAMS-WH-01/2019IEPI ISL 402123 BetaCoV/Wuhan/IVDC-HB-01/2019|EPI ISL 402119 BetaCoV/Wuhan/IVDC-HB-04/2020 EPI ISL 402120 BetaCoV/Wuhan/IVDC-HB-05/2019 EPI ISL 402121 BetaCoV/Wuhan/WIV04/2019IEPI ISL 402124 MG772933 Bat SARS-related CoV (bat-SL-CoVZC45) NC 004718 Human SARS-related CoV (e.g. Frankfurt-1) NC 014470 Bat SARS-related CoV (BM48-31/BGR/2008)

E_Sarbeco_F	E_Sarbeco_P1	E_Sarbeco_R				
ACAGGTACGTTAATAGTTAATAGCGT	ACACTAGCCATCCTTACTGCGCTTCG	ATTGTGTGCGTACTGCTGCAATAT				
· · C · · · · · · · · · · · · · · · · ·	· · C · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·				


N Sarbeco P

	n_odibood_i	
		• • • • • • • • • • • • • • • • • • • •
CACATTGGCACCCGCAATC	ACTTCCTCAAGGAACAACATTGCCA	CAAGCCTCTTCTCGTTCCTC
		\cdots \cdot
		· · · · · · · · · · · · · · C · · · · ·
· · · · · · · · · · · · G · · · · · ·	$GT \cdot A \cdot \cdot A \cdot \cdot \cdot \cdot T \cdot \cdot T \cdot \cdot C \cdot \cdot \cdot \cdot \cdot$	· · · · · · · · · C · · G · · · · · TAA

Banded karyotyping

- A karyotype is the number and appearance of chromosomes in the nucleus of a eukaryotic cell.
- Karyotypes describe the number of chromosomes, and what they look like under a light microscope.
 - Abnormal number of chromosomes
 - Large duplications and deletions
 - Balanced rearrangements (translocations, inversions)

G-banding is obtained with Giemsa stain following digestion of chromosomes with trypsin. It yields a series of lightly and darkly stained bands — the dark regions tend to be heterochromatic, late-replicating and AT rich. The light regions tend to be euchromatic, early-replicating and GC rich.



In normal diploid organisms, autosomal chromosomes are present in two copies.

Contra -		CORDER NO.	(Branchille)		Sponta to
and the second	and a				12
8 (B) 13	BB	15	16	17 17	ត្តិ ត្តិ ព័
8 B	88	10 a	8 B	A CONTRACTOR	Y

M. Seria Care and the 5 ч 1 2 ş N. 14 12 11 0. 9 10. 6 読み 0.00 t. ŝ 8 100 15 17 1.5 14 15 16 18 22 21 20 19 х medgen.genetics.uta